1 terminated, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
Follow Oligonucleotides, Antisense: new trials by email Literature Review of Oligonucleotides, Antisense trials Research Report on Oligonucleotides, Antisense
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients Inotersen - Amyloidosis | Phase 2 | Terminated | Brigham and Women's Hospital | 31 | 2019-02-28 | 2026-02-20 |
| The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart Isis 420915/GSK 299872 - Amyloidosis | Phase 2 | Withdrawn | Brigham and Women's Hospital | 2016-01-01 | 2016-08-10 |
Amyloidosis (2)
Brigham and Women's Hospital (2)
United States (1)
Rodney Falk, MD (1) · Rodney H Falk, MD (1)